PRESENT VIEW ON THE PROBLEMS OF ATHEROSCLEROSIS: REVIEW OF MATERIALS OF THE 84RD CONGRESS OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY
Abstract
The 84rd European Atherosclerosis Society (EAS) Congress was held in Innsbruck, Austria, 28 May-1 June 2016. The Congress program discussed the latest scientific data and clinical studies. Angiogenesis and vascular metabolism, familial hypercholesterolemia, obesity, lifestyle and cardiovascular diseases, personalized medicine were the main topics of the discussion. The review was prepared based on the EAS Congress 2016 materials and the websitehttp://www.eas2016.kenes.com/.
About the Authors
D. E. Ivanoshchuk
FSBSE «Scientific Research institute of therapy and preventive medicine»
Russian Federation
Russian Federation
E. V. Shakhtshneider
FSBSE «Scientific Research institute of therapy and preventive medicine»
Russian Federation
Russian Federation
References
1. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. doi: 10.1093/eurheartj/ehw106
2. Nordestgaard BG, Langsted A, Mora S et al. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory European Federation of Clinical Chemistry and Laboratory Medicine. Joint Publication: Eur Heart J. 2016 Apr 26. pii: ehw152. [Epub ahead of print] and Clin Chem. 2016 May 27. pii: clinchem.2016.258897. [Epub ahead of print]
3. http://www.eas2016.kenes.com/Documents/ Opening%20Cermony%20Highlights.pdf
4. Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014;35:2146-57.
5. Wang Y, McNutt MC, Banfi S et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl AcadSci USA 2015;112:11630-5.
6. Musunuru K, Pirruccello JP, Do R et al. Exome Sequencing, ANGPTL3Mutations, and Familial Combined Hypolipidemia. N Engl J Med 2010;363:2220-7.
7. Pisciotta L, Favari E, Magnolo L et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. CircCardiovasc Genet 2012;5:42-50.
8. Gusarova V, Alexa CA, Wang Y et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res 2015;56:1308-17.
9. Gaudet D, Gipe DA, Khoury É et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: a single arm, open-label, proof of concept study.84nd EAS Congress, Innsbruck, Austria, May 29 - June 1, 2016.P. 247.
10. Gaudet D, Saheb S, Bruckert E et al. A pilot study of MBX 8025 in the treatment of Homozygous Familial Hypercholesterolemia (HoFH). 84nd EAS Congress, Innsbruck, Austria, May 29 - June 1, 2016. P. 244.
11. Raal FJ, Honarpour N, Blom DJ et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. lipid-lowering therapy. Circulation 2011;124:2202-7.
12. Raal FJ, Pilcher GJ, Panz VR et al. Reductionin mortality in subjects with homozygous familialhypercholesterolemia associated with advances.
13. World Health Organization. Obesity and overweight (2015). Available at http://www.who.int/ mediacentre/factsheets/fs311/en/
14. Fischer J, Lefèvre C, Morava E et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Gen 2007; 39:28-30.
15. Bartlet A, Heeren J. Adipose tissue browning and metabolic health. J Nat Rev Endocrinol 2014;10:24- 36.
16. Chu AY, Workalemahu T, Paynter NP et al. Novel locus including FGF21 is associated with dietary macronutrient intake. Hum Mol Genet 2013;22:1895- 902.
17. Talukdar S, Owen BM, Song P et al. FGF21 regulates sweet and alcohol preference. Cell Metab 2016;23:344-9.
18. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med 2013;369:1336-43.
19. Wen CP, Wu X. Stressing harms of physical inactivity to promote exercise. Lancet 2012;380:192-3.
20. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. doi: 10.1093/eurheartj/ehw106
21. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
22. Gieger C, Geistlinger L, Altmaier E et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008;4: e1000282.
23. Altmaier E, Menni C, Heier M et al. The pharmacogenetic footprint of ACE inhibition: A population-based metabolomics study. PLoS One 2016;11: e0153163.
24. Shin SY, Fauman EB, Petersen AK et al. An atlas of genetic influences on human blood metabolites. Nat Genet 2014;46:543-50.
25. Finan B, Yang B, Ottaway N et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015;21:27- 36.
26. UPDATED: Ionis shares plunge as safety crisis deepens, GSK abandons PhIII. https://www. fiercebiotech.com/ionis-reveals-safety-issues-two-phiii-studies-after-gsk-delays-a-trial
Review
For citations:
Ivanoshchuk D.E., Shakhtshneider E.V. PRESENT VIEW ON THE PROBLEMS OF ATHEROSCLEROSIS: REVIEW OF MATERIALS OF THE 84RD CONGRESS OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY. Ateroscleroz. 2016;12(3):78-84. (In Russ.)
Views:
264
Email this article 